Can adding a targeted antibody to radiation keep lymphoma away?
NCT ID NCT01473628
First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This study looks at whether adding the drug rituximab to standard radiation therapy helps people with early-stage follicular lymphoma stay cancer-free longer. About 81 patients with stage I or II low-grade lymphoma are being randomly assigned to get radiation alone or radiation plus rituximab. The goal is to see if the combination improves progression-free survival without major side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rituximab (a monoclonal antibody that helps the immune system attack cancer cells)
- What this could lead to
- If it works, this could improve the chance of keeping early-stage follicular lymphoma from coming back after radiation therapy.
- What could go wrong
- This is an early-phase trial with only 81 participants, so results may not be definitive. Adding rituximab may increase side effects without guaranteeing better outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE I GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.